SNSE — Sensei Biotherapeutics Inc
NASDAQ · Healthcare · Biotechnology
Sensei Biotherapeutics Inc (SNSE) is a biotechnology company listed on NASDAQ. It is led by Christopher W. Gerry J.D., based in 1405 Research Boulevard, Rockville, MD, United States, 20850, with about 29 employees. Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Net income was -$16.4M. SNSE currently screens at market cap $18.6M.
Use this SNSE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SNSE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SNSE SEC filings page. Lician reads the product cache first so this HTML stays unique to Sensei Biotherapeutics Inc even when a live quote feed is slow.
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
SNSE Key Statistics
Market Cap
$18.59M
P/B Ratio
1.26
EPS
-$1.20
Revenue
$0.00
Net Income
-$30.16M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
29
SNSE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$30.16M | -$34.10M | -$48.59M | -$36.79M |
| EPS (Diluted) | -$1.20 | -$1.22 | -$1.58 | -$1.33 |
Total Assets
$45.36M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$9.99M
Operating Cash Flow
-$24.67M
Free Cash Flow
$0.00
Sensei Biotherapeutics Inc Company Information
- President, General Counsel, Secretary & Director
- Christopher W. Gerry J.D.
- Headquarters
- 1405 Research Boulevard, Rockville, MD, United States, 20850
- Website
- www.senseibio.com
- Phone
- 240 243 8000
- IPO / Founded
- 2021-02-04
- Sector
- Healthcare
- Industry
- Biotechnology